Optimizing vector production and purification to enhance scalable AAV manufacturing

The constant growth in the number of clinical trials in the gene therapy space highlights the need for a reliable and scalable viral vector manufacturing solution. This article describes scaling up AAV production using the Gibco™ AAV MAX helper-free AAV production system and presents a purification wash and elution optimization study using the POROS™ CaptureSelect™ AAVX chromatography resin.

Please enter your email to access content Read now